Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KY-0301 first-in-human phase I/II study in advanced solid tumors
ChiCTR2600116103Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of KY-0301 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), Pulmonary squamous cell carcinoma and 4 more (9 arms), sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicities during DLT observation period and Incidence and severity of adverse events. Started Jan 2026; status: recruiting.
02
Drugs
KY-0301
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinomacolorectal cancer (CRC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600116103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116103.